The first transatlantic flight. Breaking the sound barrier. Running a 4-minute mile. All notable “firsts” that were thought to be near impossible before they were achieved. Recently, our researchers achieved another notable first for people living with hemophilia A.
Data presented at an international congress earlier this year showed that Bioverativ’s investigational therapy for hemophilia A, BIVV001, had broken through the von Willebrand ceiling for the very first time. For decades, scientists had been working to overcome the von Willebrand factor ceiling, which limits the time - or half-life - that a factor VIII replacement therapy can stay in the body to provide protection from bleeding. Importantly, this accomplishment has the potential to transform the treatment paradigm for people with hemophilia A.